• 1
    Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand S-E, Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H++ K+) ATPase. Nature 1981; 290: 159161.
  • 2
    Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270276.
  • 3
    Wallmark B, Lorentzon P, Larsson H. The mechanism of action of omeprazole—a survey of its inhibitory actions in vitro. Scand J Gastroenterol 1985; 20: (Suppl. 108), 3751.
  • 4
    Bardhan KD, Bianchi-Porro G, Bose K, Daly M, Hinchliffe RF, Jonsson E, Lazzaroni M, Naesdal J, Rikner L, Walan A. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcer. J clin Gastroenterol 1986; 8: 408413.
  • 5
    Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, Meuwissen S-GM, Lamers CBHW. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987; i: 349351.
  • 6
    Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, Rutgersson K, Eriksson S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. New Engl J Med 1989; 320: 6975.
  • 7
    Andersson T. Pharmacokinetics of omeprazole in man: with special reference to single and repeated administration, drug interactions and polymorphic metabolism. PhD. Thesis, University of Göteborg, Sweden.
  • 8
    Regårdh CG, Andersson T, Lagerström PO, Lundborg P, Skånberg I. The pharmacokinetics of omeprazole in humans—a study of single intravenous and oral doses. Ther Drug Monit 1990; 12: 163172.
  • 9
    Lind T, Andersson T, Skånberg I, Olbe L. Biliary excretion of intravenous [14C] omeprazole in humans. Clin Pharmac Ther 1987; 42: 504508.
  • 10
    Renberg L, Simonsson R, Hoffman KJ. Identification of two main urinary metabolites of [14C]omeprazole in humans. Drug Metab Dispos 1989; 17: 6976.
  • 11
    Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmac Ther 1990; 47: 7985.
  • 12
    Andersson, T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415416.
  • 13
    Andersson T, Regårdh C-G, Lou Y-C, Zhang Y, Dahl M-L, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 2531.
  • 14
    Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmac exp Ther 1992; 262: 11951202.
  • 15
    Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30: 34273455.
  • 16
    McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P450. Cancer Res 1990; 50: 33673376.
  • 17
    Meier UT, Dayer P, Male PJ, Kronbach T, Meyer UA. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmac Ther 1985; 38: 488494.
  • 18
    Robson RA, Matthews AP, Miners JO, McManus ME, Meyer UA, Hall PM, Birkett DJ. Characterisation of theophylline metabolism by human liver microsomes. Br J clin Pharmac 1987; 24: 293300.
  • 19
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J biol Chem 1951; 193: 265275.
  • 20
    Andersson T, Lagerström PO, Miners JO, Veronese ME, Weidolf L, Birkett DJ. High performance liquid chromatographic assay for human liver microsomal omeprazole metabolism. J Chromatogr 1993; (in press).
  • 21
    Holford NHG. Mk Model: a modelling tool for microcomputers. Pharmacokinetic evaluation and comparison with standard computer programmes. Clin exp Pharmac Physiol 1985; Suppl., 9: 95.
  • 22
    Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, McManus ME. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J clin Pharmac 1991; 31: 125130.
  • 23
    Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as an in vitro substrate probe for human CYP2E1 using cDNA-expression and microsomal kinetic techniques. Biochem Pharmac 1993; (in press).
  • 24
    Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmac exp Ther 1993; 265: 401407.
  • 25
    Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de-la-Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br J clin Pharmac 1990; 29: 651663.
  • 26
    Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 13221329.
  • 27
    Yun CH, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol Pharmac 1991; 40: 679685.
  • 28
    Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA, Birkett DJ. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533538.
  • 29
    Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J clin Pharmac 1984; 26: 753759.
  • 30
    Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmac 1986; 30: 287295.
  • 31
    Inaba T, Jurima M, Mahon WA, Kalow M. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985; 13: 443448.
  • 32
    Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168179.
  • 33
    Pessayre D, Tinel M, Larrey D, Cobert B, Funck-Brentano C, Babany G. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J Pharmac exp Ther 1983; 224: 685691.